Our data and knowledge have made a significat contribution to drug development worldwide

We use our technology to support all aspects of preclinical drug discovery and biomedical translational research with a particular focus on disease of the nervous system.

Publications
Posters

Posters

NeuroSolutions has been performing first class contract research since 2001 and continues to support the biopharmaceutical industry in developing new treatments for diseases occurring throughout the central and peripheral nervous system.

Browse the breadth and depth of NeuroSolutions publications detailing our experience in rodent and non-human primate tissues.

2024

Prophylactic Tetrodotoxin Treatment of a Rat Model of Oxaliplatin-Induced Peripheral Neuropathy.

2022

An Electrophysiological Examination on the Mechanism of Action of Tetrodotoxin for the Treatment of Chemotherapy-induced Neuropathic Pain in a Rat Model of Oxaliplatin-Induced Peripheral Neuropathy.

LAT peptide motifs - a novel class of naturally derived peptide motifs and a target family of receptors that represents a unique, non-opioid, non-addictive mechanism for the treatment of neuropathic pain.

2018

Functional re-organisation of synaptic activity and intrinsic membrane conductances in dorsal horn neurones of neuropathic rats and the effects of gabapentin in vitro.

2016

In vitro electrophysiological recordings of multiple brain regions from aged pig tailed Macaques.

Vc1.1, an alpha-conotoxin reverses mechanical allodynia and inhibits ectopic discharge in neuropathic pain models.

2014

Ectopic discharge in surgically- and chemotherapeutically-induced neuropathic pain models: an electrophysiological comparison.

2012

NP260 and analogs are GABA-A receptor antagonists with novel subtype selectivity that inhibit excessive neuronal excitation and reduce allodynia in rats with neuropathic pain.

Inhibition of TRPV4 reduces the activity of mechano-sensory afferent fibers of urinary bladder in rats with cyclophosphamide-induced cystitis.

Differential effects of sumatriptan, administered pre- and post-sensitisation, on spontaneous activity and mechanical responses of trigeminal neurones in three rat models of migraine.

2011

Effects of fatty acid amide hydrolase (FAAH) inhibitors on dorsal root afferent-mediated synaptic transmission in dorsal horn spinal cord neurones of adult rats in vitro.

Telemetric recording of ectopic discharge and EEG in neuropathic rats – its application in evaluating analgesic and sedative actions of compounds.

2010

A rodent in vitro sciatic nerve DRG and dorsal root preparation in naïve and CCI model animals.

Selective blockade of NR2B subunit containing NMDA receptors enhances AMPA receptor-mediated EPSPs and sub-maximal LTP in hippocampal CA-1 pyramidal neurons through disinhibitory effects.

2009

Electrophysiological, pharmacological and molecular profile of the transiently outward rectifying conductance in neonatal rat sympathetic preganglionic neurones in vitro.

An in vivo study of the site of action of SD118/SNL043 in cci rats.

Potentiation of reflex blinks by glyceryl trinitrate in the rat: A novel model for migraine.

2008

Predicting Anxiety Related Behaviour – Using Spatial Learning Test.

2007

Effects of nitric oxide on electrotonically coupled neonatal rat SPN in vitro and in vivo.

Pregnenolone sulphate potentiates NMDA-receptor mediated responses in vitro and in vivo.

2006

Identification of two gating modes of Nav1.8

Behavioural and electrophysiological study on a Rat model of paclitaxel-induced Neuropathy.

Murine Models of Neuropathic Pain.

Comparison Of Electrophysiological Properties of Nociceptive Dorsal Root Ganglion (DRG) Neurons in vivo In Mouse and Rat.

A novel compound, SEN606 recovers Amyloid β 1-42 induced depression of LTP in vitro.

2005

A novel COX-2 inhibitor GW406381X attenuates spontaneous ectopic discharge of sural nerve in rats with chronic constriction injury (CCI).

 

"Thank you for the absolutely phenomenal work you have done for Redpin. As biotech managers, we frequently push CROs to the max and sometimes take them for granted. After reviewing the work that you have done over the past year, I felt that I needed to let you know what a difference you had made to Redpin’s growth and success. Your work has been of the highest caliber and your dedication unmatched."

Elma Hawkins PhD, MBA, former President and CEO Redpin Therapeutics, Inc.

"I have worked with NeuroSolutions on many projects over many years. The quality of the data is second to none, their scientific expertise and collaborative approach to our technicality demanding projects has been excellent. For example, the work on SEN1576 has led to high-impact joint publications with Senexis and this compound is now being developed by Talisman Therapeutics.."

Dr Mark Treherne - As former Chief Executive of Senexis Limited (Dr Treherne is currently Chief Executive of Life Sciences Organisation at UK Trade & Investment, which helps UK business trade overseas).

In partnership with
Science Exchange
Pacific Discovery Services
scientist.com
NeuroSolutions Ltd

Email: info@nsolns.com
Contact Head-office on +44 (0) 8454 500171


One of our partner companies may be better suited to your requirements

AUSTRALASIA
Pacific Discovery Services

Email: info@pacificdiscoveryservices.com